No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
BioSpace
December 1, 2020
BioSpace
FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D., M.P.H. in that role. Dr. Yu will continue as Chief Medical Officer through December 20, 2020, the roxadustat PDUFA date, and will remain with FibroGen through March 15, 2021 serving as Executive Advisor to the CEO to support the transition. Dr. Yu joined FibroGen in 2008 and has provided key leadership
Is a
Company attributes
Location
Crunchbase
Parent organization
